Protein Polymer CEO to Provide Product Development Update at Life Sciences
Investment Forum
SAN DIEGO, Jan. 20 -- Protein Polymer Technologies,
Inc. (Nasdaq: PPTI), President and Chief Executive Officer, J. Thomas Parmeter,
will present an update on the Company's development of tissue augmentation
and tissue adhesive products at the 5th Annual Musculoskeletal Life Sciences
Investment Forum in Boston on January 27, 1999.
The Company recently filed an Investigational Device
Exemption (IDE) with the U.S. Food and Drug Administration requesting approval
to initiate clinical trials for treatment of female stress urinary incontinence.
In addition to reporting preclinical performance of its unique urethral
bulking agent, Dr. Parmeter will discuss PPTI's plans, pending FDA approval,
for human clinical trials in women suffering from stress urinary incontinence.
These trials are anticipated to begin in the second quarter of 1999.
He will also outline the Company's progress toward clinical testing of its
injectable dermal augmentation product for use in cosmetic and reconstructive
surgery, and the Company's strategy going forward in 1999 and into the 21st
Century, including new information on the potential utility of the Company's
tissue adhesive and sealant technology in major orthopedic applications.
Protein Polymer Technologies, Inc., is a San Diego-based
company focused on developing products to improve medical and surgical outcomes.
From its inception in 1988, PPTI has been a pioneer in protein design and
synthesis, developing an extensive portfolio of proprietary biomaterials.
These genetically engineered biomaterials are high molecular weight proteins,
processed into products with physical and biological characteristics tailored
to specific clinical performance requirements. Targeted products include
urethral bulking agents for the treatment of stress urinary incontinence,
dermal augmentation products for cosmetic and reconstructive surgery, tissue
adhesives and sealants, scaffolds for wound healing and tissue engineering,
and depots for local drug delivery.
